KRONOS BIO INC (KRON) Stock Analyst Ratings
NASDAQ:KRON - Nasdaq - US50107A1043 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 83% to KRON. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 2.3. This target is 160.8% above the current price.
KRON was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about KRON.
In the previous month the buy percentage consensus was at a similar level.
KRON was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-14 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-11-14 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-10-08 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-19 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-12-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-04-17 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-18 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-10 | Goldman Sachs | Maintains | Buy |
| 2022-11-09 | Piper Sandler | Maintains | Overweight |
| 2022-09-14 | Berenberg | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2022-02-28 | Piper Sandler | Maintains | Overweight |
| 2021-11-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-06-24 | HC Wainwright & Co. | Initiate | Buy |